Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 06/14/21 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
2 | |
| 06/09/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 06/09/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 06/08/21 | 8-K | Current report filing |
|
2 | |
| 06/04/21 | EFFECT | Notice of Effectiveness |
|
1 | |
| 05/28/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 05/28/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 05/28/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 05/25/21 | DEF 14A | Definitive proxy statements |
|
16 | |
| 05/21/21 | 8-K | Current report filing |
|
2 |
